CVRx, Inc. (CVRX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.40

From 52W high−84.28%

Volume362966.00

Market cap$42.09M

P/E (TTM)—

P/S (TTM)0.7x

Div yield—

Key dataNov 4, 2026

Open

$1.40

From 52W high

−84.28%

Volume

362966.00

Market cap

$42.09M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.8x

P/E (TTM)

—

RSI (14)

39.5

MomentumView details →

1D Return

+14.49%

YTD Return

−79.08%

SummaryUpdated Jun 1, 2026

CVRx, Inc. (NASDAQ:CVRX) is a commercial-stage medical device company founded in 2000 and headquartered in Minneapolis, Minnesota. The company went public in June 2021 and specializes in developing neuromodulation solutions for cardiovascular diseases. CVRx has established itself as a pioneer in the emerging field of cardiovascular neuromodulation, focusing primarily on treating heart failure through its flagship Barostim device. After more than two decades of development and clinical testing, the company has successfully commercialized its technology and is actively expanding its market presence in the United States and Europe.

Ask drillr about CVRx, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.8x

EV/Sales

0.6x

P/S (TTM)

0.7x

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

86.60%

Net Margin

−84.93%

EBITDA Margin

−73.80%

ROE (TTM)

−260.45%

ROA (TTM)

−56.31%

Asset Turnover

0.64x

GrowthView details →

Revenue YoY

+11.96%

EPS YoY

+5.71%

FCF YoY

−4.13%

Revenue CAGR 3Y

+36.11%

EPS CAGR 3Y

+23.02%

EBITDA YoY

+2.16%

MomentumView details →

1D Return

+14.49%

YTD Return

−79.08%

1Y Return

−84.83%

RSI (14)

39.5

vs 50D SMA

−31.27%

vs 200D SMA

−71.57%

Capital & dividendView details →

Debt/Equity

2.98x

Current Ratio

8.04x

Quick Ratio

6.87x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.53

EPS Surprise

−1.03%

Beats (12Q)

8/12

Next Q EPS Est

−$0.49

Avg Surprise (4Q)

−1.65%

Rev Surprise

1.00%

Financials snapshotView financials →

Revenue (TTM)

61.19M

Net Income (TTM)

−51.97M

Op. CF (TTM)

−40.46M

Next earningsNov 5, 2026 →

Latest newsMore news →

CVRx announced the schedule of scientific presentations featuring its Barostim neuromodulation therapy at the Heart Failure Society of America Annual Scientific Meeting 2026.36d ago

Similar companies

Davion Healthcare PlcDAVI Inspira Technologies Oxy B.H.N. Ltd.IINN Hyperion DeFi, Inc.HYPD TELA Bio, Inc.TELA Spectral AI, Inc.MDAI InspireMD, Inc.NSPR Find similar companies →

Latest newsMore news →

CVRx, Inc. announced that it plans to release its third-quarter 2026 financial and operating results after market close on November 5, 2026, and host a conference call at 4:30 p.m. Eastern Time that day.13d ago CVRx announced the schedule of scientific presentations featuring its Barostim neuromodulation therapy at the Heart Failure Society of America Annual Scientific Meeting 2026.36d ago